Visit the Oxoid web site
Click on the advert above to visit the company web site

Product category: Microbiology
News Release from: Oxoid | Subject: PBP2'
Edited by the Laboratorytalk Editorial Team on 30 April 2002

Test for MRSA and MRCoNS receives FDA
approval

The first rapid latex test to be approved for the confirmation of resistance in both staphylococcus aureus and coagulase negative staphylococci

The Oxoid PBP2' test has received FDA approval for the identification of MRSA and MRCoNS, making this the first rapid latex test to be approved for the confirmation of resistance in both staphylococcus aureus and coagulase negative staphylococci Confirming the presence of penicillin binding protein (PBP2' - the protein encoded by the MecA gene) by latex agglutination is an accurate and reliable method for detecting oxacillin/methicillin resistance, with the PBP2' test demonstrating 100% accuracy compared to PCR

Furthermore, PBP2' is much quicker and easier to perform than genotypic tests, yielding clearly visible results in just a few minutes.

On evaluating the test in the United States, Mary York, a highly respected opinion leader in the field of antimicrobial susceptibility testing, commented, "I'm very excited about this new method.

I would see Oxoid PBP2' being used either as a confirmatory test or a rapid test to get the patient on the right antibiotics." Oxoid PBP2' conforms to the NCCLS guidelines for the detection of oxacillin resistance (M100-S12). Request a free brochure from Oxoid ...

Oxoid: contact details and other news
Email this article to a colleague
Register for the free Laboratorytalk email newsletter
Laboratorytalk Home Page

Search the Pro-Talk network of sites

Visit the Oxoid web site